141 related articles for article (PubMed ID: 36400926)
1. Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
Ling VY; Straube J; Godfrey W; Haldar R; Janardhanan Y; Cooper L; Bruedigam C; Cooper E; Tavakoli Shirazi P; Jacquelin S; Tey SK; Baell J; Huang F; Jin J; Zhao Y; Bullinger L; Bywater MJ; Lane SW
Leukemia; 2023 Jan; 37(1):143-153. PubMed ID: 36400926
[TBL] [Abstract][Full Text] [Related]
2. Mitocurcumin utilizes oxidative stress to upregulate JNK/p38 signaling and overcomes Cytarabine resistance in acute myeloid leukemia.
Gaur T; Ali A; Sharma D; Gupta SK; Gota V; Bagal B; Platzbeckar U; Mishra R; Dutt A; Khattry N; Mills K; Hassan MI; Sandur S; Hasan SK
Cell Signal; 2024 Feb; 114():111004. PubMed ID: 38048856
[TBL] [Abstract][Full Text] [Related]
3. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
Schenk EL; Koh BD; Flatten KS; Peterson KL; Parry D; Hess AD; Smith BD; Karp JE; Karnitz LM; Kaufmann SH
Clin Cancer Res; 2012 Oct; 18(19):5364-73. PubMed ID: 22869869
[TBL] [Abstract][Full Text] [Related]
4.
Fu JF; Shih LY; Yen TH
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080665
[TBL] [Abstract][Full Text] [Related]
5. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
7. Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
Hege Hurrish K; Qiao X; Li X; Su Y; Carter J; Ma J; Kalpage HA; Hüttemann M; Edwards H; Wang G; Kim S; Dombkowski A; Bao X; Li J; Taub JW; Ge Y
Biochem Pharmacol; 2022 Nov; 205():115283. PubMed ID: 36208684
[TBL] [Abstract][Full Text] [Related]
8. Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis.
Li L; Han C; Yu X; Shen J; Cao Y
J Healthc Eng; 2022; 2022():2842066. PubMed ID: 35126914
[TBL] [Abstract][Full Text] [Related]
9. Coculture in vitro with endothelial cells induces cytarabine resistance of acute myeloid leukemia cells in a VEGF-A/VEGFR-2 signaling-independent manner.
Okamoto S; Miyano K; Kitakaze K; Kato H; Yamauchi A; Kajikawa M; Itsumi M; Kawai C; Kuribayashi F
Biochem Biophys Res Commun; 2022 Jan; 587():78-84. PubMed ID: 34872003
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure.
Radosevic N; Delmer A; Tang R; Marie JP; Ajchenbaum-Cymbalista F
Leukemia; 2001 Apr; 15(4):559-66. PubMed ID: 11368357
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
Porter CC; Kim J; Fosmire S; Gearheart CM; van Linden A; Baturin D; Zaberezhnyy V; Patel PR; Gao D; Tan AC; DeGregori J
Leukemia; 2012 Jun; 26(6):1266-76. PubMed ID: 22289989
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
Nakatani K; Matsuo H; Harata Y; Higashitani M; Koyama A; Noura M; Nishinaka-Arai Y; Kamikubo Y; Adachi S
Int J Hematol; 2021 Feb; 113(2):243-253. PubMed ID: 33068248
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
[TBL] [Abstract][Full Text] [Related]
14. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
15. Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
Khoury H; He R; Schimmer A; Beadle JR; Hostetler KY; Minden MD
Chemotherapy; 2018; 63(4):225-237. PubMed ID: 30372692
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
[TBL] [Abstract][Full Text] [Related]
17. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
18. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
Pigneux A; Mahon FX; Uhalde M; Jeanneteau M; Lacombe F; Milpied N; Reiffers J; Belloc F
Exp Hematol; 2008 Dec; 36(12):1648-59. PubMed ID: 18922616
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
20. Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling.
Su Q; Huang P; Luo X; Zhang P; Li H; Chen Y
Hematology; 2023 Dec; 28(1):2255802. PubMed ID: 37815490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
